Trial
NCT02525302
HT-100 Long-term Study in DMD Patients Who Completed HALO-DMD-02
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Akashi Therapeutics
Collaborators
—
Condition
Duchenne Muscular Dystrophy
Intervention
HT-100
Why stopped
Dosing stopped
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-03-12